Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Micron (M) shares along with other memory stocks like Sandisk, neoclouds Nebius and Coreweave, and chip makers Nvidia, AMD, and Intel are all moving after concerns of an AI development slowdown came to a head this weekend. Potential beneficiaries of the changing AI trade could be the software sector.
- Oracle (ORCL) shares are lower as Chairman Larry Ellison canceled his plan to sell as many as 50 million shares in the tech company, a holding worth $7.5 billion.
- Rum Group (RUM), formerly known as Rumble, is rallying as much as 28% in premarket trading on Monday after the Information reports that Anthropic has struck a $13.7 billion compute pact with the firm.
- Johnson & Johnson (JNJ) shares are moving on news Apollo is in discussions to acquire the Johnson & Johnson orthopedics unit, known as DePuy Synthes. Apollo is in talks to value the unit at close to $20 billion, and an agreement could be reached within several weeks.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Chipmakers and other artificial intelligence-related firms slide, weighing on US stock futures, as leaders of some of the biggest AI companies called for a slower pace of development of their most advanced and lucrative models.
- IAG and other airline stocks are dipping as airfares are poised to stay elevated for longer after oil prices rise, dashing hopes of travelers expecting lower ticket prices over the Christmas holiday period.
- Cerillion shares drop as much as 21%, the most on record, after the billings software provider said full-year revenue will be below consensus expectations due to customer order delays.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator.
- AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts.
See omnystudio.com/listener for privacy information.

Bloomberg’s Nathan Hager focuses on three stocks for the week ahead. They include: Lennar, Salesforce, and Take-Two.

Nathan previews what to expect from these companies in the week ahead with Avalon Pernell, Bloomberg Equities Reporter.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers, we take a look at some of the week's biggest gainers and decliners:
- Shares of Skyworks (SWKS) surged after CEO Philip Brace updated investors about the status of a key merger. The stock gained 26%, the best five-day session streak since a stretch in February 2009.
- Lululemon's (LULU) turnaround won't be a quick or easy fix as the company cedes market share to rivals and suffers deepening sales declines, according to BMO Capital Markets. BMO initiated coverage of the stock with an underperform rating and a $70 price target, assuming a roughly 29% decline from where the shares closed on Friday. Analysts say the company's "irrelevance with the consumer is showing up in the numbers" and that Lululemon will need to cut prices or liquidate merchandise to reinvigorate demand, which will also pressure margins. During trading on Friday, share rose to just under $100 per share at the close in New York. While the average price target of about $100 is near where shares traded at Friday’s close, the stock has slumped 52% this year and is down more than 80% from a December 2023 record.
- Cooper (COO) led the decliners in health care and lowered its full-year-outlook. On Thursday, it saw its shares tumble as much as 20%, the most intraday since 2008.
See omnystudio.com/listener for privacy information.